Dr. Eric Whitman MD
Medical Director, Office of Grants and Research, ATLANTIC HEALTH SYSTEM INC
Member of the Healthcare Council
Council Member Biography
Eric Whitman, MD, is the Medical Director of the Office of Grants and Research for Atlantic Health System in Morristown, New Jersey. He is a board certified General Surgeon with fellowship training in surgical oncology. He specializes in melanoma care, endocrine and oncologic surgery. Dr. Whitman is also the founding Director of the Atlantic Health Melanoma Center, a clinical and research Center of Excellence within the Carol G. Simon Cancer Center of Morristown Memorial Hospital and Overlook Hospital. He specializes in endocrine and oncologic surgery, with particular emphasis in melanoma care and minimally-invasive endocrine surgery for diseases of the thyroid, parathyroid, and adrenal glands. Dr. Whitman has an active surgical practice and participates in multiple research studies to treat melanoma, with particular interest in novel combinations of immunotherapeutic, chemotherapeutic, and targeted agents. (This is me - Update Profile)
Employment History
- 2007 - 2007
- Medical Director of Cancer Center, Mountainside Hospital
- 2006 - Unspecified
- Medical Director, Office of Grants and Research, ATLANTIC HEALTH SYSTEM INC
- 2004 - 2007
- Chairman/Admin Director, Mountainside Hospital
- 2004 - Unspecified
- Founding Director of Melanoma Center, ATLANTIC HEALTH SYSTEM
- 1998 - 2004
- Partner, CIO, SUBURBAN SURGICAL ASSOCIATES
- 1992 - 1998
- Assistant Professor, THE WASHINGTON UNIVERSITY
GLG NewsSM Analyses by Eric Whitman(?)
Opinions and analyses expressed in GLG News are solely those of the author. See the Terms of Use for details.
-
Synta Drug for Metastatic Melanoma Not Dead Yet (?)
November 3, 2009
Synta Pharmaceuticals Announces Updated Elesclomol SYMMETRYSM Data Presented at Melanoma XIII | www.businesswire.com
Updated data presented at an annual Melanoma conference suggests the drug Elesclomol may benefit a subset of patients treated on a Phase III trial. This Synta Pharmaceuticals-sponsored trial in metastatic melanoma patients was stopped for safety (survival) concerns in February 2009, but the updated analysis suggests that a commonly available biomarker may identify patients who appear to benefit from Elesclomol treatment.This news is important because it may allow Synta to continue to pursue approval for Elesclomol in either melanoma patients or in other cancers. They will report an updated survival analysis twelve months after the protocol was stopped, after February 2010. Further info from Synta is expected soon.
-
Delcath Phase III trial for metastatic melanoma completes enrollment
November 3, 2009
Delcath Systems, Inc. Completes Phase III Study Enrollment | www.reuters.com
The Delcath Systems Percutaneous Hepatic Perfusion (PHP) trial to treat patients with metastatic melanoma has completed enrollment and now must track patients, record data, and analyze results.This trial was apparently enrolled on schedule and the company is targeting 2010 for FDA regulatory submission.
-
Plexxikon Drug for Melanoma Continues to Show Great Promise
October 14, 2009
Researchers herald 'breakthrough' skin cancer therapy | www.fiercebiotech.com
The new drug PLX-4032, being developed by Plexxikon and Roche, continues to show impressive short term results in melanoma patients with specific BRAF mutations, with a reported 70% tumor response rate.
-
Gleevec shows promise as targeted melanoma treatment
July 27, 2009
A phase II study of imatinib mesylate (IM) for patients with advanced melanoma harboring somatic alterations of KIT | meeting.ascopubs.org
Gleevec (Imatinib), a target specific cancer treatment drug against KIT oncogene mutations, shows early evidence of efficacy in treating melanomas with susceptible genetic mutations, further support for a personalized medicine, targeted therapy, approach to treating melanoma and cancers in general.
-
PLX-4032, the new great hope for targeted therapy in melanoma
July 27, 2009
Plexxikon announces PLX4032 Phase I Data showing objective responses in metastatic melanoma patients | www.plexxikon.com
PLX-4032, a Plexxikon drug being co-developed with Roche, has shown remarkable results in a Phase I trial for melanoma and appears poised for rapid progression through Phase II and Phase III testing with perhaps accelerated FDA approval on the horizon.
Leading institutions connect with Eric Whitman through GLG
GLG Study Groups with Eric Whitman(?)
| Study Group Name | No. Members |
|---|---|
| Oncologists (US) | 2241 |
| Physicians who Treat Malignant Melanoma (US) | 179 |
| Oncologists Using Da Vinci Robotic System | 147 |
| Skin Cancer Oncologists (US) | 108 |
| Nexavar Prescribers: Oncologists | 73 |
GLG Live Meetings with Eric Whitman(?)
Eric Whitman has not participated in any GLG Live Meetings.